To clarify I wrote to Mr Gennadi as he is listed as the investor relations contact on the annexures. Dont have a direct contact into the company unfortunately although some LTHs here may have better luck if they do in getting a more complete response from Diamond. In other biotech companies i trade ive seen responses as quick as within 5 minutes by email from the CEO which would have been nice on this occasion. Either way its a good opportunity if the market has mispriced the info
Ann: ANP Updates on US Regulatory Plans for ATL1102 in DMD, page-118
-
- There are more pages in this discussion • 57 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
